UK markets closed

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.33-7.23 (-49.66%)
At close: 4:00PM EDT
Full screen
Loading interactive chart…
  • This Is How You Could Have Anticipated Orphazyme's Implosion
    Motley Fool

    This Is How You Could Have Anticipated Orphazyme's Implosion

    A lot of everyday investors recently lost a bundle betting that the Food and Drug Administration would approve an experimental drug from Orphazyme (NASDAQ: ORPH). There were reasons to suspect arimoclomol might earn approval to treat a rare life-threatening disease. There were also plenty of reasons to keep your portfolio far away from Orphazyme's attempt to earn approval for its first drug.

  • Here's Why Orphazyme Stock Is Imploding Today
    Motley Fool

    Here's Why Orphazyme Stock Is Imploding Today

    Shares of Orphazyme (NASDAQ: ORPH), a clinical-stage biopharmaceutical company, are getting hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC).